InflammatoryAmgen presents new IGF-1R inhibitorsAmgen Inc. has identified insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors reported to be useful for the treatment of inflammatory disorders, autoimmune disease, cancer, diabetes, psoriasis, atherosclerosis, fibrosis and thyroid-associated ophthalmopathy, among others.